Human Papillomavirus Infections - Pipeline Review, H2 2015
Summary
Global Markets Directs, Human Papillomavirus Infections - Pipeline Review, H2 2015, provides an overview of the Human Papillomavirus Infectionss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Human Papillomavirus Infections Overview 8
Therapeutics Development 9
Pipeline Products for Human Papillomavirus Infections - Overview 9
Pipeline Products for Human Papillomavirus Infections - Comparative Analysis 10
Human Papillomavirus Infections - Therapeutics under Development by Companies 11
Human Papillomavirus Infections - Therapeutics under Investigation by Universities/Institutes 13
Human Papillomavirus Infections - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Human Papillomavirus Infections - Products under Development by Companies 18
Human Papillomavirus Infections - Products under Investigation by Universities/Institutes 22
Human Papillomavirus Infections - Companies Involved in Therapeutics Development 23
3M Drug Delivery Systems 23
Admedus Ltd 24
Agilvax, Inc. 25
Astex Pharmaceuticals, Inc. 26
Beijing Minhai Biotechnology Co., Ltd 27
Bharat Biotech International Limited 28
Biogenomics Limited 29
BioMAS Ltd. 30
Biota Pharmaceuticals, Inc. 31
Chongqing Zhifei Biological Products Co., Ltd. 32
Crucell N.V. 33
EpiPharm AG 34
FluGen, Inc. 35
Foamix Pharmaceuticals Ltd. 36
G&E Herbal Biotechnology Co., Ltd. 37
Genticel S.A. 38
Helix BioPharma Corp. 39
Immunservice GmbH 40
Indian Immunologicals Limited 41
Kaketsuken K.K. 42
LEO Pharma A/S 43
MediGene AG 44
NanoViricides, Inc. 45
Nielsen Biosciences, Inc. 46
Novan, Inc. 47
Novartis AG 48
Organic Vaccines 49
Promius Pharma, LLC 50
RXi Pharmaceuticals Corporation 51
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 52
Shanghai Zerun Biotechnology Co., Ltd. 53
Spider Biotech 54
Starpharma Holdings Limited 55
Tamir Biotechnology, Inc. 56
Zydus Cadila Healthcare Limited 57
Human Papillomavirus Infections - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 62
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
(digoxin + furosemide) - Drug Profile 68
854-A - Drug Profile 69
ABI-1968 - Drug Profile 70
aminolevulinic acid hydrochloride - Drug Profile 71
AS-101 - Drug Profile 72
Aspidasept - Drug Profile 74
astodrimer - Drug Profile 75
AX-03 - Drug Profile 77
BTA-074 - Drug Profile 78
Candida Albicans Antigen - Drug Profile 80
Cell Therapy for Human Papillomavirus Infection - Drug Profile 81
DFD-05 - Drug Profile 82
diphencyprone - Drug Profile 83
EPI-N06 - Drug Profile 84
GTL-002 - Drug Profile 85
Herpecide - Drug Profile 86
HPV virus like particle vaccine - Drug Profile 87
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile 88
human papilloma virus [types 16 and 18] vaccine - Drug Profile 89
human papilloma virus [types 16, 18] (bivalent) virus like particle vaccine - Drug Profile 90
human papilloma virus vaccine - Drug Profile 91
human papilloma virus vaccine - Drug Profile 92
human papillomavirus (tetravalent) vaccine - Drug Profile 93
human papillomavirus [serotypes 16, 31] virus like particle vaccine - Drug Profile 94
human papillomavirus vaccine - Drug Profile 96
human papillomavirus vaccine - Drug Profile 97
human papillomavirus vaccine - Drug Profile 98
human papillomavirus vaccine - Drug Profile 99
human papillomavirus vaccine - Drug Profile 100
human papillomavirus vaccine - Drug Profile 101
human papillomavirus vaccine - Drug Profile 102
hydrogen peroxide - Drug Profile 103
imiquimod - Drug Profile 104
ingenol mebutate - Drug Profile 105
interferon alfa-2b (recombinant) - Drug Profile 107
interferon alpha-2b (recombinant) - Drug Profile 108
ISANIL-01 - Drug Profile 110
LFX-453 - Drug Profile 111
NTP-01 - Drug Profile 112
NVN-1000 - Drug Profile 113
onalespib - Drug Profile 115
PL-202 - Drug Profile 118
PP-210 - Drug Profile 119
ProCervix - Drug Profile 120
ranpirnase - Drug Profile 122
RKP-00156 - Drug Profile 125
SB-105A10 - Drug Profile 126
SB-206 - Drug Profile 128
sinecatechins - Drug Profile 129
Small Molecules for HPV Infections - Drug Profile 130
SRT-100 - Drug Profile 132
Synthetic Peptides for Viral Infections - Drug Profile 134
Vaccine for Cervical Cancer and Genital Warts - Drug Profile 135
Human Papillomavirus Infections - Recent Pipeline Updates 136
Human Papillomavirus Infections - Dormant Projects 148
Human Papillomavirus Infections - Discontinued Products 152
Human Papillomavirus Infections - Product Development Milestones 153
Featured News & Press Releases 153
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160
List of Tables
Number of Products under Development for Human Papillomavirus Infections, H2 2015 13
Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Comparative Analysis by Unknown Stage Development, H2 2015 21
Products under Development by Companies, H2 2015 22
Products under Development by Companies, H2 2015 (Contd..1) 23
Products under Development by Companies, H2 2015 (Contd..2) 24
Products under Development by Companies, H2 2015 (Contd..3) 25
Products under Investigation by Universities/Institutes, H2 2015 26
Human Papillomavirus Infections - Pipeline by 3M Drug Delivery Systems, H2 2015 27
Human Papillomavirus Infections - Pipeline by Admedus Ltd, H2 2015 28
Human Papillomavirus Infections - Pipeline by Agilvax, Inc., H2 2015 29
Human Papillomavirus Infections - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 30
Human Papillomavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 31
Human Papillomavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2015 32
Human Papillomavirus Infections - Pipeline by Biogenomics Limited, H2 2015 33
Human Papillomavirus Infections - Pipeline by BioMAS Ltd., H2 2015 34
Human Papillomavirus Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2015 35
Human Papillomavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 36
Human Papillomavirus Infections - Pipeline by Crucell N.V., H2 2015 37
Human Papillomavirus Infections - Pipeline by EpiPharm AG, H2 2015 38
Human Papillomavirus Infections - Pipeline by FluGen, Inc., H2 2015 39
Human Papillomavirus Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 40
Human Papillomavirus Infections - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 41
Human Papillomavirus Infections - Pipeline by Genticel S.A., H2 2015 42
Human Papillomavirus Infections - Pipeline by Helix BioPharma Corp., H2 2015 43
Human Papillomavirus Infections - Pipeline by Immunservice GmbH, H2 2015 44
Human Papillomavirus Infections - Pipeline by Indian Immunologicals Limited, H2 2015 45
Human Papillomavirus Infections - Pipeline by Kaketsuken K.K., H2 2015 46
Human Papillomavirus Infections - Pipeline by LEO Pharma A/S, H2 2015 47
Human Papillomavirus Infections - Pipeline by MediGene AG, H2 2015 48
Human Papillomavirus Infections - Pipeline by NanoViricides, Inc., H2 2015 49
Human Papillomavirus Infections - Pipeline by Nielsen Biosciences, Inc., H2 2015 50
Human Papillomavirus Infections - Pipeline by Novan, Inc., H2 2015 51
Human Papillomavirus Infections - Pipeline by Novartis AG, H2 2015 52
Human Papillomavirus Infections - Pipeline by Organic Vaccines, H2 2015 53
Human Papillomavirus Infections - Pipeline by Promius Pharma, LLC, H2 2015 54
Human Papillomavirus Infections - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 55
Human Papillomavirus Infections - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 56
Human Papillomavirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015 57
Human Papillomavirus Infections - Pipeline by Spider Biotech, H2 2015 58
Human Papillomavirus Infections - Pipeline by Starpharma Holdings Limited, H2 2015 59
Human Papillomavirus Infections - Pipeline by Tamir Biotechnology, Inc., H2 2015 60
Human Papillomavirus Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 61
Assessment by Monotherapy Products, H2 2015 62
Assessment by Combination Products, H2 2015 63
Number of Products by Stage and Target, H2 2015 65
Number of Products by Stage and Mechanism of Action, H2 2015 67
Number of Products by Stage and Route of Administration, H2 2015 69
Number of Products by Stage and Molecule Type, H2 2015 71
Human Papillomavirus Infections Therapeutics - Recent Pipeline Updates, H2 2015 140
Human Papillomavirus Infections - Dormant Projects, H2 2015 152
Human Papillomavirus Infections - Dormant Projects (Contd..1), H2 2015 153
Human Papillomavirus Infections - Dormant Projects (Contd..2), H2 2015 154
Human Papillomavirus Infections - Dormant Projects (Contd..3), H2 2015 155
Human Papillomavirus Infections - Discontinued Products, H2 2015 156
List of Figures
Number of Products under Development for Human Papillomavirus Infections, H2 2015 13
Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 62
Number of Products by Top 10 Targets, H2 2015 64
Number of Products by Stage and Top 10 Targets, H2 2015 64
Number of Products by Top 10 Mechanism of Actions, H2 2015 66
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 66
Number of Products by Top 10 Routes of Administration, H2 2015 68
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 68
Number of Products by Top 10 Molecule Types, H2 2015 70
Number of Products by Stage and Top 10 Molecule Types, H2 2015 70
